<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">BMC Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">BMC Bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>BMC Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1471-2105</issn>
    <publisher>
      <publisher-name>BioMed Central</publisher-name>
      <publisher-loc>London</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7092414</article-id>
    <article-id pub-id-type="publisher-id">3449</article-id>
    <article-id pub-id-type="doi">10.1186/s12859-020-3449-2</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Methodology Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>QuaDMutNetEx: a method for detecting cancer driver genes with low mutation frequency</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Bokhari</surname>
          <given-names>Yahya</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff2">2</xref>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Alhareeri</surname>
          <given-names>Areej</given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">4</xref>
        <xref ref-type="aff" rid="Aff5">5</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9215-5522</contrib-id>
        <name>
          <surname>Arodz</surname>
          <given-names>Tomasz</given-names>
        </name>
        <address>
          <email>tarodz@vcu.edu</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0458 8737</institution-id><institution-id institution-id-type="GRID">grid.224260.0</institution-id><institution>Department of Computer Science, College of Engineering, Virginia Commonwealth University, </institution></institution-wrap>401 W. Main St., Richmond, VA 23284 USA </aff>
      <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0580 0891</institution-id><institution-id institution-id-type="GRID">grid.452607.2</institution-id><institution>Department of Biostatistics and Bioinformatics, King Abdullah International Medical Research Center, </institution></institution-wrap>Riyadh, Saudi Arabia </aff>
      <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0608 0662</institution-id><institution-id institution-id-type="GRID">grid.412149.b</institution-id><institution>King Saud bin Abdulaziz University for Health Sciences, </institution></institution-wrap>Riyadh, Saudi Arabia </aff>
      <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0608 0662</institution-id><institution-id institution-id-type="GRID">grid.412149.b</institution-id><institution>College of Applied Medical Sciences, King Saud bin Abdulaziz University for Health Sciences, </institution></institution-wrap>Riyadh, Saudi Arabia </aff>
      <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0580 0891</institution-id><institution-id institution-id-type="GRID">grid.452607.2</institution-id><institution>King Abdullah International Medical Research Center, </institution></institution-wrap>Riyadh, Saudi Arabia </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>23</day>
      <month>3</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>23</day>
      <month>3</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2020</year>
    </pub-date>
    <volume>21</volume>
    <elocation-id>122</elocation-id>
    <history>
      <date date-type="received">
        <day>15</day>
        <month>5</month>
        <year>2019</year>
      </date>
      <date date-type="accepted">
        <day>10</day>
        <month>3</month>
        <year>2020</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2020</copyright-statement>
      <license license-type="OpenAccess">
        <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <sec>
        <title>Background</title>
        <p id="Par1">Cancer is caused by genetic mutations, but not all somatic mutations in human DNA drive the emergence or growth of cancers. While many frequently-mutated cancer driver genes have already been identified and are being utilized for diagnostic, prognostic, or therapeutic purposes, identifying driver genes that harbor mutations occurring with low frequency in human cancers is an ongoing endeavor. Typically, mutations that do not confer growth advantage to tumors – passenger mutations – dominate the mutation landscape of tumor cell genome, making identification of low-frequency driver mutations a challenge. The leading approach for discovering new putative driver genes involves analyzing patterns of mutations in large cohorts of patients and using statistical methods to discriminate driver from passenger mutations.</p>
      </sec>
      <sec>
        <title>Results</title>
        <p id="Par2">We propose a novel cancer driver gene detection method, QuaDMutNetEx. QuaDMutNetEx discovers cancer drivers with low mutation frequency by giving preference to genes encoding proteins that are connected in human protein-protein interaction networks, and that at the same time show low deviation from the mutual exclusivity pattern that characterizes driver mutations occurring in the same pathway or functional gene group across a cohort of cancer samples.</p>
      </sec>
      <sec>
        <title>Conclusions</title>
        <p id="Par3">Evaluation of QuaDMutNetEx on four different tumor sample datasets show that the proposed method finds biologically-connected sets of low-frequency driver genes, including many genes that are not found if the network connectivity information is not considered. Improved quality and interpretability of the discovered putative driver gene sets compared to existing methods shows that QuaDMutNetEx is a valuable new tool for detecting driver genes. QuaDMutNetEx is available for download from <ext-link ext-link-type="uri" xlink:href="https://github.com/bokhariy/QuaDMutNetEx">https://github.com/bokhariy/QuaDMutNetEx</ext-link>under the GNU GPLv3 license.</p>
      </sec>
    </abstract>
    <kwd-group xml:lang="en">
      <title>Keywords</title>
      <kwd>Somatic mutations</kwd>
      <kwd>Cancer pathways</kwd>
      <kwd>Driver mutations</kwd>
      <kwd>Protein-protein interaction networks</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution>National Science Foundation</institution>
        </funding-source>
        <award-id>1453658</award-id>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>© The Author(s) 2020</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1">
    <title>Background</title>
    <p>Cancer driver mutations are DNA changes that are causally implicated in oncogenesis [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Typically between two and eight mutations, targeting several cellular pathways, are needed for cancer to develop [<xref ref-type="bibr" rid="CR3">3</xref>]. To disrupt a single pathway or a group of functionally related genes in a way that promotes cancer growth, often only one mutation is needed [<xref ref-type="bibr" rid="CR4">4</xref>–<xref ref-type="bibr" rid="CR6">6</xref>].</p>
    <p>Most DNA mutations are not cancer drivers. Mutations in DNA accumulate throughout life – for example, comparing skin or gastrointestinal epithelium cells in cancer samples from patients 85 and 25 years old showed that the younger patient on average has half the number of mutation compared to the older patient. More than half of all mutations found in cancer tissue are estimated to have occurred before the start of the disease [<xref ref-type="bibr" rid="CR7">7</xref>]. Additionally, mutation rate tends to increase in cancer cells [<xref ref-type="bibr" rid="CR8">8</xref>], although it can differ significantly even among subclones within the tumor [<xref ref-type="bibr" rid="CR9">9</xref>]. Most of these new random mutations do not contribute to the progression of the disease. An analysis of large number of cancer samples gathered in the Cancer Genome Atlas (TCGA) [<xref ref-type="bibr" rid="CR10">10</xref>] shows that the total number of mutations present in a tumor tissue from a single patient can range from 10 to more than 100, and only about 2 to 6 among them are driver mutations [<xref ref-type="bibr" rid="CR11">11</xref>]. Hence, the majority of mutations present in a cancer tissue sample are passenger mutations, with no positive impact on oncogenesis. Due to the potential of using driver genes, that is, genes that harbor driver mutations, for therapeutic, prognostic, or diagnostic purposes, assembling a comprehensive catalogue of driver genes an important ongoing endeavor [<xref ref-type="bibr" rid="CR12">12</xref>–<xref ref-type="bibr" rid="CR14">14</xref>]. The main challenge in this task is discovering new driver genes while avoiding false positives stemming from the abundance of passenger mutations.</p>
    <p>Statistical and computational methods for detecting driver genes often rely on finding certain pattern of mutations in a group of driver genes across a cohort of patients. To develop cancer, multiple cellular functions must be perturbed, and in different patients, different genes with the same function may be mutated. Often, the cancer develops and is detected before a second mutation in genes with a given function occurs. Thus, for a given cancer type, for a group of patients, each patient would have at least one mutation in a functionally-related group of driver genes, but rarely would have more than one mutation – the gene set exhibits mutual exclusivity pattern of mutations. Several methods detect a set of driver genes by quantifying mutual exclusivity, including Dendrix [<xref ref-type="bibr" rid="CR15">15</xref>] and Multi-Dendrix [<xref ref-type="bibr" rid="CR16">16</xref>], RME [<xref ref-type="bibr" rid="CR17">17</xref>], CoMEt [<xref ref-type="bibr" rid="CR18">18</xref>], TiMEx [<xref ref-type="bibr" rid="CR19">19</xref>], MEMo [<xref ref-type="bibr" rid="CR20">20</xref>], and our own method, QuaDMutEx [<xref ref-type="bibr" rid="CR21">21</xref>]. An alternative approach involves knowledge of networks linking genes. Frequently mutated genes and their less-frequently mutated neighbors in known human gene- or protein-level pathways or networks are detected as drivers. Methods such as HotNet2 [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>], MEMo [<xref ref-type="bibr" rid="CR20">20</xref>] and DriverNet [<xref ref-type="bibr" rid="CR24">24</xref>] adopted the network-oriented driver detection approach.</p>
    <p>Biological network connectivity and mutual exclusivity are both important sources of information in discovering driver genes. At the same time, both types of information must be used with caution. The available biological networks are incomplete and are expected to include false positives, which might affect the true structure of the network in a way that is unknown. Deviations from mutual exclusivity pattern are expected in individual patients, especially in slow-growing tumors where random mutations have more time to accumulate before cancer is detected. Therefore, an algorithm that uses biological networks and mutual exclusivity at the same time will be able to utilize two complementary, imperfect sources of information to improve the quality of the discovered putative driver gene sets.</p>
    <p>We propose a tool, QuaDMutNetEx, which combines the network and exclusivity based approaches. As in our previous tool QuaDMutEx [<xref ref-type="bibr" rid="CR21">21</xref>], the objective function that is used to select driver genes penalizes for any deviation from the mutual exclusivity pattern. Additionally, QuaDMutNetEx shows preference for genes that are connected in known human biological networks. Compared to mutual exclusivity-based tools such as QuaDMutEx or Dendrix, this additional source of information can help in finding rare driver mutations, for which neither the network connectivity and mutation frequency alone, nor exclusivity alone, are selective enough. The tool models both the network and the mutual exclusivity terms of the objective function as convex, quadratic terms, resulting in a binary quadratic problem, which is solved using our previously proposed technique of efficiently exploring the space of gene sets by using stochastic search through a series of globally optimal solutions to subproblems. Comparisons with existing state-of-the-art methods on four cancer datasets show that the approach of combining network and exclusivity approaches results in improved ability to detect highly connected, mutually exclusive rare driver genes.</p>
  </sec>
  <sec id="Sec2" sec-type="results">
    <title>Results</title>
    <p>We evaluated QuaDMutNetEx using its default parameters that have been selected experimentally: the maximum size of the gene set is <italic>ν</italic>=50; <italic>k</italic>=1, indicating equal preference for optimizing coverage and excess coverage; <italic>C</italic>=2.5; the network parameter was set to <italic>α</italic>=0.3; the number of iterations was set to <italic>T</italic>=10,000. In the network-connectivity term of the objective function, we used combined three human protein-protein interaction networks previously used in HotNet2 [<xref ref-type="bibr" rid="CR23">23</xref>]. The first network is the iRefIndex network, which consists of 91,872 interactions among 12,338 proteins. The second network is MultiNet network which consists of 109,597 interactions among 14,445 proteins. The last network is HINT+HI2012 which is created by considering two interactome databases: HI-2012 data in human HI2 Interactome database, HI2012, and high-quality interactomes database, HINT. The HINT+HI2012 network consists of 40,783 interactions among 10,008 proteins.</p>
    <p>We used four datasets to evaluate the proposed algorithm: triple-negative breast cancer (TN), glioblastoma multiforme (GBM), high-grade serous ovarian cancer (HGS), and another breast cancer (METABRIC) dataset (see Table <xref rid="Tab1" ref-type="table">1</xref>). These datasets were previously used in evaluating the DriverNet tool. Following standard practice, known hypermutated genes such as mucins, titin, olfactory receptors, which are unlikely to play role in cancer, were removed [<xref ref-type="bibr" rid="CR25">25</xref>].
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Summary of DriverDB tool datasets used in experimental validation of QuaDMutNetEx</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Dataset</th><th align="left">Samples (n)</th><th align="left">Genes (p)</th><th align="left">Mutations</th></tr></thead><tbody><tr><td align="justify">TN: triple negative breast cancer</td><td align="left">94</td><td align="left">4594</td><td align="left">6007</td></tr><tr><td align="justify">GBM: glioblastoma multiforme</td><td align="left">120</td><td align="left">3747</td><td align="left">8141</td></tr><tr><td align="justify">HGS: high-grade serous ovarian cancer</td><td align="left">316</td><td align="left">13278</td><td align="left">22897</td></tr><tr><td align="justify">METABRIC: breast cancer</td><td align="left">696</td><td align="left">13076</td><td align="left">51255</td></tr></tbody></table></table-wrap></p>
    <sec id="Sec3">
      <title>Quantitative and qualitative assessment of QuaDMutNetEx results</title>
      <p>The results of the tests, presented in Table <xref rid="Tab2" ref-type="table">2</xref>, show that the proposed method returns gene sets that are statistically significant at 0.05. To assess statistical significance of the results returned by QuaDMutNetEx, we used permutation test proposed in [<xref ref-type="bibr" rid="CR15">15</xref>]. In short, we randomly permuted the patient-gene matrix in a way that preserves the number of mutations in each patient, and in each gene. This process results in a randomized dataset in which any correlations of mutations are only appearing by chance, but the gene mutation frequencies and patient mutation counts are the same as in the original dataset, which keeps the randomized dataset similar to the original. We created 256 randomized datasets and ran QuaDMutNetEx on each dataset. To obtain a <italic>p</italic>-value estimate, the final penalty score obtained from running QuaDMutNetEx on the original dataset was compared with the distribution of final penalty scores from running QuaDMutNetEx on the 256 randomized datasets.
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Quantitative characteristics of QuaDMutNetEx results</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Dataset</th><th align="left">Genes Found</th><th align="left">Estimated <italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left">TN</td><td align="left">13</td><td align="left">&lt;0.004</td></tr><tr><td align="left">GBM</td><td align="left">6</td><td align="left">&lt;0.004</td></tr><tr><td align="left">HGS</td><td align="left">25</td><td align="left">0.016</td></tr><tr><td align="left">METABRIC</td><td align="left">25</td><td align="left">&lt;0.004</td></tr></tbody></table><table-wrap-foot><p>Solutions for all four datasets are statistically significant at <italic>p</italic>&lt;0.05</p></table-wrap-foot></table-wrap></p>
      <p>The genes discovered by QuaDMutNetEx are presented in Table <xref rid="Tab3" ref-type="table">3</xref>. To evaluate the gene’s driver status, we used COSMIC Cancer Gene Census database [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>] and the cancer driver gene database DriverDBv2 [<xref ref-type="bibr" rid="CR28">28</xref>]. To check QuaDMutNetEx’s effectiveness in discovering rare cancer drivers, we focused on the genes in the solutions that are least frequently mutated in the datasets, and preformed literature review to analyze if these are true or false positives. Additionally, we visually evaluated the resulting gene networks – the largest connected component for each dataset is presented in Fig. <xref rid="Fig1" ref-type="fig">1</xref>. To show how inclusion of the network connectivity term in the objective function improves the solution, we have denoted genes found on the same datasets by our mutual-exclusivity-only method, QuaDMutEx. We see that most of the discovered driver genes, especially those mutated with low frequency, result from including the network connectivity term.
<fig id="Fig1"><label>Fig. 1</label><caption><p>Known interactions between driver genes discovered by QuaDMutNetEx on the four datasets: TN: triple-negative breast cancer, GBM: glioblastoma multiforme, HGS: high-grade serous ovarian cancer, and METABRIC: breast cancer</p></caption><graphic xlink:href="12859_2020_3449_Fig1_HTML" id="MO1"/></fig>
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Putative driver gene sets discovered by QuaDMutNetEx</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Gene</th><th align="left">c</th><th align="left">D/R</th><th align="left">QuanDMutEx</th><th align="left">COSMIC</th><th align="left">DDBv2</th><th align="left">Gene</th><th align="left">c</th><th align="left">D/R</th><th align="left">QuanDMutEx</th><th align="left">COSMIC</th><th align="left">DDBv2</th></tr></thead><tbody><tr><td align="left"><bold>TN: Triple-negative breast cancer</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">TP53</td><td align="left">35</td><td align="left">R</td><td align="left">✓</td><td align="left">✓</td><td align="left">✓</td><td align="left">PARK2</td><td align="left">6</td><td align="left">∙</td><td align="left">✓</td><td align="left">∙</td><td align="left">✓</td></tr><tr><td align="left">ATR</td><td align="left">4</td><td align="left">D</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td><td align="left">SAGE1</td><td align="left">3</td><td align="left">∙</td><td align="left">✓</td><td align="left">∙</td><td align="left">✓</td></tr><tr><td align="left">NR3C1</td><td align="left">3</td><td align="left">∙</td><td align="left">✓</td><td align="left">∙</td><td align="left">✓</td><td align="left">CREBBP</td><td align="left">2</td><td align="left">D/R</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td></tr><tr><td align="left">DAPK1</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">NCOA1</td><td align="left">2</td><td align="left">D</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td></tr><tr><td align="left">SLC39A7</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">IDH3B</td><td align="left">2</td><td align="left">∙</td><td align="left">✓</td><td align="left">∙</td><td align="left">✓</td></tr><tr><td align="left">HIST1H4A</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">HIF1A</td><td align="left">2</td><td align="left">D</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td></tr><tr><td align="left">MLL</td><td align="left">2</td><td align="left">D</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"><bold>GBM: Glioblastoma multiforme</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">CDKN2A</td><td align="left">55</td><td align="left">R</td><td align="left">✓</td><td align="left">✓</td><td align="left">✓</td><td align="left">TP53</td><td align="left">38</td><td align="left">R</td><td align="left">✓</td><td align="left">✓</td><td align="left">✓</td></tr><tr><td align="left">MDM2</td><td align="left">13</td><td align="left">D</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td><td align="left">MDM4</td><td align="left">5</td><td align="left">D</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td></tr><tr><td align="left">MAPK9</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">RPL11</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td></tr><tr><td align="left"><bold>HGS: high-grade serous ovarian cancer</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">TP53</td><td align="left">249</td><td align="left">R</td><td align="left">✓</td><td align="left">✓</td><td align="left">✓</td><td align="left">SOS1</td><td align="left">3</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td></tr><tr><td align="left">CTNNB1</td><td align="left">2</td><td align="left">D</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td><td align="left">DAG1</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td></tr><tr><td align="left">ERBB2</td><td align="left">2</td><td align="left">D</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td><td align="left">FANCA</td><td align="left">2</td><td align="left">R</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td></tr><tr><td align="left">GRB2</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">PIK3R1</td><td align="left">2</td><td align="left">R</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td></tr><tr><td align="left">TSHR</td><td align="left">2</td><td align="left">D</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td><td align="left">DNAJA3</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td></tr><tr><td align="left">HSP90AA1</td><td align="left">2</td><td align="left">D</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td><td align="left">HSPA5</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td></tr><tr><td align="left">MST1R</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">PTK2</td><td align="left">2</td><td align="left">∙</td><td align="left">✓</td><td align="left">∙</td><td align="left">✓</td></tr><tr><td align="left">STAT3</td><td align="left">2</td><td align="left">D</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td><td align="left">UBC</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td></tr><tr><td align="left">VAV3</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">WRN</td><td align="left">2</td><td align="left">R</td><td align="left">✓</td><td align="left">✓</td><td align="left">✓</td></tr><tr><td align="left">ZAP70</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">ERBB3</td><td align="left">2</td><td align="left">D</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td></tr><tr><td align="left">NTRK2</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">SPRY2</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td></tr><tr><td align="left">DHHC11</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">JAK2</td><td align="left">2</td><td align="left">D</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td></tr><tr><td align="left">CDKN2A</td><td align="left">2</td><td align="left">R</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"><bold>METABRIC: breast cancer</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">ERBB2</td><td align="left">84</td><td align="left">D</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td><td align="left">FGFR1</td><td align="left">50</td><td align="left">D</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td></tr><tr><td align="left">GAB2</td><td align="left">35</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">PSG11</td><td align="left">28</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td></tr><tr><td align="left">MACROD2</td><td align="left">19</td><td align="left">∙</td><td align="left">✓</td><td align="left">∙</td><td align="left">✓</td><td align="left">PTEN</td><td align="left">16</td><td align="left">D</td><td align="left">✓</td><td align="left">✓</td><td align="left">✓</td></tr><tr><td align="left">FRS2</td><td align="left">10</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">IGF1R</td><td align="left">10</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td></tr><tr><td align="left">CRK</td><td align="left">10</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">JAK2</td><td align="left">7</td><td align="left">D</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td></tr><tr><td align="left">AC116165.7-2</td><td align="left">6</td><td align="left">∙</td><td align="left">✓</td><td align="left">∙</td><td align="left">∙</td><td align="left">IRS4</td><td align="left">6</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td></tr><tr><td align="left">PTK2</td><td align="left">5</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">IL6ST</td><td align="left">4</td><td align="left">D</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td></tr><tr><td align="left">EGFR</td><td align="left">4</td><td align="left">D</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td><td align="left">GRB2</td><td align="left">4</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td></tr><tr><td align="left">PTPN1</td><td align="left">4</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">CREBBP</td><td align="left">3</td><td align="left">D/R</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td></tr><tr><td align="left">DOK6</td><td align="left">3</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">JAK1</td><td align="left">2</td><td align="left">D</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td></tr><tr><td align="left">EGF</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">PIK3R1</td><td align="left">2</td><td align="left">R</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td></tr><tr><td align="left">SYK</td><td align="left">2</td><td align="left">D</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td><td align="left">PTPN6</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td></tr><tr><td align="left">VAV1</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr></tbody></table><table-wrap-foot><p>Number of patients in the dataset that had a mutation in the gene is in c column. D/R stand for dominant or recessive otherwise unknown. Genes discovered by the quadratic mutual-exclusivity approach that does not include the network connectivity term are in QuanDMutEx column. COSMIC [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>] column represent if the gene present in COSMIC Cancer Gene Census. Genes present in DriverDBv2 [<xref ref-type="bibr" rid="CR28">28</xref>] are in DDBv2 column</p></table-wrap-foot></table-wrap></p>
      <p>In the triple-negative breast cancer (TN) dataset, out of thirteen identified driver genes, eight are each mutated in only two out of 94 patients, and are analyzed below. A chromatin-remodeling gene CREBBP was found to be overexpressed in breast cancers [<xref ref-type="bibr" rid="CR29">29</xref>], and is frequently mutated in bladder cancers [<xref ref-type="bibr" rid="CR30">30</xref>]. DAPK1 is a potential tumor suppressor gene [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. NCOA1 was found to promote angiogenesis in breast cancers [<xref ref-type="bibr" rid="CR33">33</xref>]. SLC39A7 is a potential oncogene in colorectal cancer [<xref ref-type="bibr" rid="CR34">34</xref>]. IDH3B is upregulated in breast cancer and is significantly involved in energy metabolism in tumor progression [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. HIST1H4A is known to play a role in cell death induction in tumor cells [<xref ref-type="bibr" rid="CR37">37</xref>]. HIF1A functions as a tumor promoter in cancer-associated fibroblasts, and as a tumor suppressor in breast cancer cells, also it is already a vaccine target in triple-negative breast cancer [<xref ref-type="bibr" rid="CR38">38</xref>–<xref ref-type="bibr" rid="CR40">40</xref>]. Finally, MLL methyltransferase are known to have a haematopoietic-specific tumorigenic capability [<xref ref-type="bibr" rid="CR41">41</xref>].</p>
      <p>In the ovarian cancer (HGS) dataset, twenty-three out of twenty-five identified genes are low-frequency driver genes – each is mutated only in two out of 316 patients. Of these twenty-three genes, CTNNB1 is implicated in malignant ovarian transformation [<xref ref-type="bibr" rid="CR42">42</xref>]. DAG1 and HSPA5 are already drug targets [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. ERBB2, MST1R, STAT3, VAV3, ERBB3, NTRK2 and JAK2 are known oncogenes [<xref ref-type="bibr" rid="CR45">45</xref>–<xref ref-type="bibr" rid="CR50">50</xref>], and FANCA is a potential oncogene [<xref ref-type="bibr" rid="CR51">51</xref>]. GRB2 is a therapeutic target for solid tumor prevention [<xref ref-type="bibr" rid="CR52">52</xref>]. PIK3R1 represents a critical driver of endometrial cancer pathogenesis and is a therapeutic target [<xref ref-type="bibr" rid="CR53">53</xref>]. TSHR signaling promotes the proliferation of ovarian cancer [<xref ref-type="bibr" rid="CR54">54</xref>]. HSP90AA1 is considered as a potential protein target in therapy of ovarian cancer. [<xref ref-type="bibr" rid="CR55">55</xref>]. UBC is potential drug resistance-related gene in ovarian cancer [<xref ref-type="bibr" rid="CR56">56</xref>]. Finally, WRN and CDKN2A are tumor suppressor genes [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>].</p>
      <p>In the glioblastoma multiforme (GBM) dataset, out of six identified driver genes, one is mutated in five, and two in only two out of 120 patients. Of these, MAPK9 was found to be significantly upregulated in glioma stem cells [<xref ref-type="bibr" rid="CR59">59</xref>]. MDM2 is a known oncogene [<xref ref-type="bibr" rid="CR60">60</xref>], while RPL11 is a tumor suppressor gene that acts together with MDM2 in p53 activation pathway [<xref ref-type="bibr" rid="CR61">61</xref>]. In the METABRIC breast cancer dataset, out of twenty five genes identified by QuaDMutNetEx, six are very rare – each mutated in only two out of 696 patients. Of these, JAK1 is known for its key role in breast cancer progression [<xref ref-type="bibr" rid="CR62">62</xref>]. EGFR signaling pathway also has a crucial role in mammary cancers [<xref ref-type="bibr" rid="CR63">63</xref>], and polymorphism in the EGFR ligand, EGF, was found to affect cancer progression [<xref ref-type="bibr" rid="CR64">64</xref>]. PIK3R1 and VAV1 are known oncogenes [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>], SYK is a tumor suppressor gene [<xref ref-type="bibr" rid="CR67">67</xref>], and PTPN6 has a tumor suppressor role [<xref ref-type="bibr" rid="CR68">68</xref>]. Together, these results confirm that QuaDMutNetEx is highly effective in identifying cancer driver genes with low mutation frequency.</p>
      <p>For comparison, we used two network-based methods, DriverNet and HotNet2. We also used a mutual exclusivity tool, Dendrix. We ran the three tools on the same four datasets: TN, GBM, HGS, and METABRIC. DriverNet was designed to utilize genomic, transcriptomic, and biological network information, HotNet2 utilizes genomic and biological network information, while Denrix used only the genomic information. In all three methods, as well as in QuaDMutNetEx, we used the default parameters. For each method, we analyzed coverage, excess coverage, conformity to the mutual exclusivity pattern as quantified by the Dendrix score <inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$n - \sum _{i=1}^{n} |G_{i} x - 1|$\end{document}</tex-math><mml:math id="M2"><mml:mi>n</mml:mi><mml:mo>−</mml:mo><mml:munderover><mml:mrow><mml:mo>∑</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:munderover><mml:mo>|</mml:mo><mml:msub><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mi>x</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo>|</mml:mo></mml:math><inline-graphic xlink:href="12859_2020_3449_Article_IEq1.gif"/></alternatives></inline-formula>, and the number of connected components in the subgraph of the biological network consisting of the genes in the solution returned by the method.</p>
    </sec>
    <sec id="Sec4">
      <title>Testing in cancer molecular subtypes dataset</title>
      <p>Mutual exclusive pattern in tumor can be resulted from other factors [<xref ref-type="bibr" rid="CR69">69</xref>]. Hence, methods using mutual exclusivity need to account for that. Here we are using GBM subtypes to test the effectiveness of our method [<xref ref-type="bibr" rid="CR69">69</xref>]. Using copy number, gene expression and methylation, GBM classified into proneural, neural, classical, and mesenchymal [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. We downloaded GBM data from TCGA and divided them into four subtypes according to TCGA IDs given in [<xref ref-type="bibr" rid="CR71">71</xref>].</p>
      <p>The genes discovered by QuaDMutNetEx are presented in Table <xref rid="Tab4" ref-type="table">4</xref>. To evaluate the gene’s driver status, we used COSMIC Cancer Gene Census database [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>] and the cancer driver gene database DriverDBv2 [<xref ref-type="bibr" rid="CR28">28</xref>]. All of the resulted genes exist in both COSMIC and DriverDB2 or one of them.
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Putative driver gene sets and metrics in GBM subtypes discovered by QuaDMutNetEx</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Gene</th><th align="left">c</th><th align="left">D/R</th><th align="left">COSMIC</th><th align="left">DDBv2</th><th align="left">Gene</th><th align="left">c</th><th align="left">D/R</th><th align="left">COSMIC</th><th align="left">DDBv2</th></tr></thead><tbody><tr><td align="left"><bold>Classical GBM</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"><bold>Metrics:</bold></td><td align="left"/><td align="left">samples</td><td align="left">genes</td><td align="left">mutations</td><td align="left">Genes in solution</td><td align="left">Coverage</td><td align="left">Excess coverage</td><td align="left">Connected components</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">n=69</td><td align="left">p=487</td><td align="center">1192</td><td align="left">6</td><td align="left">0.6232</td><td align="left">0.1163</td><td align="left">5</td><td align="left"/></tr><tr><td align="left">EGFR</td><td align="left">21</td><td align="left">D</td><td align="left">✓</td><td align="left">✓</td><td align="left">PCDHAC2</td><td align="left">15</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td></tr><tr><td align="left">DNAH9</td><td align="left">4</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">GABRA6</td><td align="left">4</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td></tr><tr><td align="left">PTPRG</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">TEK</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td></tr><tr><td align="left"><bold>Mesenchymal GBM</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"><bold>Metrics:</bold></td><td align="left"/><td align="left">samples</td><td align="left">genes</td><td align="left">mutations</td><td align="left">Genes in solution</td><td align="left">Coverage</td><td align="left">Excess coverage</td><td align="left">Connected components</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">n=75</td><td align="left">p=510</td><td align="left">1310</td><td align="left">12</td><td align="left">0.7733</td><td align="left">0.1552</td><td align="left">4</td><td align="left"/></tr><tr><td align="left">PTEN</td><td align="left">23</td><td align="left">D</td><td align="left">✓</td><td align="left">✓</td><td align="left">EGFR</td><td align="left">17</td><td align="left">D</td><td align="left">✓</td><td align="left">✓</td></tr><tr><td align="left">PIK3CA</td><td align="left">5</td><td align="left">D</td><td align="left">✓</td><td align="left">✓</td><td align="left">CPNE8</td><td align="left">3</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td></tr><tr><td align="left">KDM2B</td><td align="left">3</td><td align="left">∙</td><td align="left">✓</td><td align="left">✓</td><td align="left">NRXN1</td><td align="left">3</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td></tr><tr><td align="left">INPPL1</td><td align="left">3</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">EZR</td><td align="left">2</td><td align="left">D</td><td align="left">✓</td><td align="left">✓</td></tr><tr><td align="left">GRB10</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">IRS1</td><td align="left">2</td><td align="left">D</td><td align="left">✓</td><td align="left">✓</td></tr><tr><td align="left">IRS4</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">LZTR1</td><td align="left">2</td><td align="left">D</td><td align="left">✓</td><td align="left">✓</td></tr><tr><td align="left"><bold>Proneural GBM</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"><bold>Metrics:</bold></td><td align="left"/><td align="left">samples</td><td align="left">genes</td><td align="left">mutations</td><td align="left">Genes in solution</td><td align="left">Coverage</td><td align="left">Excess coverage</td><td align="left">Connected components</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">n=44</td><td align="left">p=229</td><td align="center">558</td><td align="left">7</td><td align="left">0.6364</td><td align="left">0.0714</td><td align="left">2</td><td align="left"/></tr><tr><td align="left">TP53</td><td align="left">15</td><td align="left">R</td><td align="left">✓</td><td align="left">✓</td><td align="left">PCDHAC2</td><td align="left">5</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td></tr><tr><td align="left">CHEK1</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">CREBBP</td><td align="left">2</td><td align="left">D/R</td><td align="left">✓</td><td align="left">✓</td></tr><tr><td align="left">DAXX</td><td align="left">2</td><td align="left">R</td><td align="left">✓</td><td align="left">✓</td><td align="left">MECOM</td><td align="left">2</td><td align="left">R</td><td align="left">✓</td><td align="left">✓</td></tr><tr><td align="left">TBP</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"><bold>Neural GBM</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"><bold>Metrics:</bold></td><td align="left"/><td align="left">samples</td><td align="left">genes</td><td align="left">mutations</td><td align="left">Genes in solution</td><td align="left">Coverage</td><td align="left">Excess coverage</td><td align="left">Connected components</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">n=41</td><td align="left">p=199</td><td align="left">482</td><td align="left">8</td><td align="left">0.6585</td><td align="left">0.0370</td><td align="left">2</td><td align="left"/></tr><tr><td align="left">TP53</td><td align="left">15</td><td align="left">R</td><td align="left">✓</td><td align="left">✓</td><td align="left">ANK2</td><td align="left">5</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td></tr><tr><td align="left">PDGFRA</td><td align="left">2</td><td align="left">D</td><td align="left">✓</td><td align="left">✓</td><td align="left">FLT1</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td></tr><tr><td align="left">PTPN11</td><td align="left">2</td><td align="left">D</td><td align="left">✓</td><td align="left">✓</td><td align="left">CHD8</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td></tr><tr><td align="left">DYNC1I1</td><td align="left">2</td><td align="left">∙</td><td align="left">∙</td><td align="left">✓</td><td align="left">KDR</td><td align="left">2</td><td align="left">D</td><td align="left">✓</td><td align="left">✓</td></tr></tbody></table><table-wrap-foot><p>Boxes below the GBM subtypes show the metrics of a GBM subtype including number of samples, number of genes etc. Discovered genes by QuaDMutNetEx are below the metrics box. Number of patients in the dataset that had a mutation in the gene is in c column. D/R stand for dominant or recessive otherwise unknown. COSMIC [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>] column represent if the gene present in COSMIC Cancer Gene Census. Genes present in DriverDBv2 [<xref ref-type="bibr" rid="CR28">28</xref>] are in DDBv2 column</p></table-wrap-foot></table-wrap></p>
    </sec>
    <sec id="Sec5">
      <title>Comparison with existing methods</title>
      <p>The quality of the solutions returned by QuaDMutNetEx is higher than solutions from other methods (see Table <xref rid="Tab5" ref-type="table">5</xref>). QuaDMutNetEx consistently produces more mutually exclusive gene sets than the network-based methods, and the gene sets are more highly connected – the interaction networks have fewer separate connected components. Compared to Dendrix, the tool that only considers mutual exclusivity, QuaDMutNetEx solutions show slightly lower mutual exclusivity, but at the same time are much more highly connected.
<table-wrap id="Tab5"><label>Table 5</label><caption><p>Comparison between QuaDMutNetEx, HotNet2, DriverNet, and Dendrix</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Method</th><th align="left">Genes in solution</th><th align="left">Coverage</th><th align="left">Excess coverage</th><th align="left">Dendrix score</th><th align="left">Connected components</th></tr></thead><tbody><tr><td align="left">TN: Triple negative breast cancer</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">HotNet2</td><td align="left">128</td><td align="left">0.6809</td><td align="left">0.7969</td><td align="left">-118</td><td align="left">9</td></tr><tr><td align="left">DriverNet</td><td align="left">21</td><td align="left">0.6383</td><td align="left">0.4667</td><td align="left">23</td><td align="left">14</td></tr><tr><td align="left">Dendrix</td><td align="left">22</td><td align="left">0.6170</td><td align="left">0.1034</td><td align="left">51</td><td align="left">8</td></tr><tr><td align="left">QuaDMutNetEx</td><td align="left">13</td><td align="left">0.6854</td><td align="left">0.0983</td><td align="left"><bold>55</bold></td><td align="left"><bold>3</bold></td></tr><tr><td align="left">GBM: Glioblastoma multiforme</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">HotNet2</td><td align="left">37</td><td align="left">0.7833</td><td align="left">0.4149</td><td align="left">10</td><td align="left">11</td></tr><tr><td align="left">DriverNet</td><td align="left">17</td><td align="left">0.9333</td><td align="left">0.8661</td><td align="left">-140</td><td align="left">9</td></tr><tr><td align="left">Dendrix</td><td align="left">22</td><td align="left">0.7166</td><td align="left">0.023256</td><td align="left"><bold>84</bold></td><td align="left">4</td></tr><tr><td align="left">QuaDMutNetEx</td><td align="left">6</td><td align="left">0.8151</td><td align="left">0.1855</td><td align="left">79</td><td align="left"><bold>1</bold></td></tr><tr><td align="left">HGS: high-grade serous ovarian cancer</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">HotNet2</td><td align="left">58</td><td align="left">0.8449</td><td align="left">0.4307</td><td align="left">83</td><td align="left">4</td></tr><tr><td align="left">DriverNet</td><td align="left">72</td><td align="left">0.9335</td><td align="left">0.6373</td><td align="left">-35</td><td align="left">51</td></tr><tr><td align="left">Dendrix</td><td align="left">3</td><td align="left">0.8037</td><td align="left">0.0</td><td align="left"><bold>254</bold></td><td align="left">3</td></tr><tr><td align="left">QuaDMutNetEx</td><td align="left">25</td><td align="left">0.6170</td><td align="left">0.1086</td><td align="left">236</td><td align="left"><bold>1</bold></td></tr><tr><td align="left">METABRIC: breast cancer</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">HotNet2</td><td align="left">224</td><td align="left">0.4424</td><td align="left">0.7394</td><td align="left">-1694</td><td align="left">18</td></tr><tr><td align="left">DriverNet</td><td align="left">90</td><td align="left">0.4683</td><td align="left">0.7785</td><td align="left">-1130</td><td align="left">33</td></tr><tr><td align="left">Dendrix</td><td align="left">18</td><td align="left">0.3836</td><td align="left">0.1236</td><td align="left"><bold>233</bold></td><td align="left">16</td></tr><tr><td align="left">QuaDMutNetEx</td><td align="left">25</td><td align="left">0.3982</td><td align="left">0.1753</td><td align="left">216</td><td align="left"><bold>4</bold></td></tr></tbody></table></table-wrap></p>
    </sec>
    <sec id="Sec6">
      <title>Effects of parameters on QuaDMutNetEx</title>
      <p>The behavior of proposed method can be adjusted by three parameters, based on the knowledge of the tumor under study. Parameter <italic>α</italic> quantifies the reward for gene connectivity in cellular networks – higher values indicate stronger preference for finding densely connected genes. Parameter <italic>k</italic> controls how steeply the penalty for multiple mutations in a single pathway grows – lower values of <italic>k</italic> lead to lower penalization of excess coverage in relation to coverage, and is appropriate for slower growing tumors, where additional mutations in any given pathway have more time to accumulate by chance. Finally, higher values of parameter <italic>C</italic> penalize for solutions sets with many genes.</p>
      <p>We have analyzed how these parameters affect the solution by running QuaDMutNetEx for 100,000 iterations for parameters <italic>α</italic>=0.01,0.05,0.1,0.3,0.6,1 with <italic>C</italic>=0.25,0.5,1,1.5,2,2.5 and <italic>α</italic>=0.01,0.05,0.1,0.3,0.6,1 with <italic>k</italic>=0.25,0.5,1,1.5,2,2.5. Figure <xref rid="Fig2" ref-type="fig">2</xref> shows that the parameter <italic>α</italic> achieves its design goal, that is, solution with higher <italic>α</italic> include fewer connected components and prefer connected network. The <italic>α</italic> parameter has the following effect on coverage and excess coverage: as the value of <italic>α</italic> increases, the coverage decreases and the excess coverage increases. Furthermore, as the value of <italic>α</italic> increases, it decreases the effect of <italic>C</italic> and <italic>k</italic>. Setting <italic>α</italic> to a low value, such as 0.001, makes the effect of <italic>C</italic> and <italic>k</italic> to be more dominant. Higher coverage and higher excess coverage, as expected, are observed for low <italic>k</italic> values. High values of <italic>C</italic> lead to solution sets involving only a few genes, while low values of <italic>C</italic> lead to high coverage.
<fig id="Fig2"><label>Fig. 2</label><caption><p>Effects of parameters on QuaDMutNetEx. <bold>a</bold>, <bold>b</bold>: effect on connected components; <bold>c</bold>, <bold>d</bold>: effect on coverage; <bold>e</bold>, <bold>f</bold>: effect on excess coverage. Results shown are for the HGS dataset, the results for other datasets are similar</p></caption><graphic xlink:href="12859_2020_3449_Fig2_HTML" id="MO2"/></fig></p>
    </sec>
  </sec>
  <sec id="Sec7" sec-type="discussion">
    <title>Discussion</title>
    <p>The proposed method, QuaDMutNetEx, relies on two sources of information to detect cancer driver genes. It uses observed somatic mutations in a cohort of cancer patients, to detect mutual exclusivity patterns, and a biological network encoding functional relationships between genes to provide context for the observed data. Relying on two sources of information is a strength of the proposed method, since treated individually, each source is imperfect. Biological networks are know to be incomplete and contain false positives, and the functional, regulatory, and signaling relationships they capture are not all directly relevant to cancer. Mutual exclusivity patterns may not be perfectly present in the observed patient mutation data. This may be true especially for slower growing tumors, where the time from onset of the disease to its detection is long enough to allow for accumulation of additional mutations in functionally-related sets of genes that contribute to cancer. Depending on the knowledge of the analyzed type of cancer and characteristics of the studied patient cohort, the users of QuaDMutNetEx should adjust the parameters of the methods that govern the strength of preference for mutual exclusivity in relation to patient coverage, the weight assigned to the network knowledge, and the strength of preference for small driver gene sets. Users of QuaDMutNetEx should also keep in mind that it uncovers driver genes relevant to the cohort from which the mutation data comes from. That is, it detects drivers present in the particular set of patients, based on the particular type of mutation data provided.</p>
  </sec>
  <sec id="Sec8" sec-type="conclusion">
    <title>Conclusions</title>
    <p>Experiments on four datasets show that QuaDMutNetEx has the ability to detect driver genes mutated with low frequency, genes that may be missed by existing tools that rely on mutual exclusivity alone, or on frequency and network information alone. Improvements in the quality and interpretability of the discovered putative driver gene sets makes QuaDMutNetEx a valuable addition to the family of driver discovery tools.</p>
  </sec>
  <sec id="Sec9">
    <title>Methods</title>
    <sec id="Sec10">
      <title>Input for QuaDMutNetEx</title>
      <p>QuaDMutNetEx input has two sources of information. The first source is the binary somatic mutation matrix as in many mutual-exclusivity tools [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Specifically, the data for <italic>n</italic> patients, each with total of <italic>p</italic> genes explored for possible existence of somatic mutations, arrives in a form of a mutation matrix <italic>G</italic>, an <italic>n</italic> by <italic>p</italic> sparse binary matrix. We expect <italic>G</italic><sub><italic>ij</italic></sub>=1 if patient <italic>i</italic> has a somatic mutation in gene <italic>j</italic>, that is, a difference between cancer tissue and matched healthy tissue from the same patient is detected; otherwise, <italic>G</italic><sub><italic>ij</italic></sub>=0. The change can be a point mutation in the coding region of the gene, potentially affecting its function. It could also be a mutation in the non-coding, regulatory elements of the DNA associated with the gene, or copy number alternation of the gene in case of homozygous deletions and high-level amplifications, affecting its expression. A row of the matrix describing mutations in patient <italic>i</italic> will be referred to as a vector <italic>G</italic><sub><italic>i</italic></sub>. The second source of information is a gene connectivity matrix <italic>A</italic>, with nonzero <italic>A</italic><sub><italic>ij</italic></sub> values for genes <italic>i</italic> and <italic>j</italic> that are known to be related in a biologically meaningful way, for example one gene regulates the other, or proteins encoded by the genes are known to interact in a signaling pathway. The output of the method is a column vector <italic>x</italic> of length <italic>p</italic>, with <italic>x</italic><sub><italic>j</italic></sub>=1 indicating that gene <italic>j</italic> is a putative cancer driver gene, that is, its mutations can contribute to cancer growth, and zero otherwise. The non-zero elements of the solution will be referred to as the solution gene set.</p>
    </sec>
    <sec id="Sec11">
      <title>Defining the quality of potential driver gene sets</title>
      <p>For the binary solution vector <italic>x</italic> with length <italic>p</italic> genes, there are 2<sup><italic>p</italic></sup>−1 possible non-zero solution vectors, each encoding a different gene set. The challenge is to find a gene set that is composed of driver genes. To this end, we designed a penalty score that reflects how likely it is that genes encoded by a solution vector form a comprehensive set of driver genes impacting a single cellular function. The lower the penalty score, the more likely the solution consists of related driver genes. The penalty score has two major terms: a network term, and a mutual-exclusivity term.</p>
      <p>The network terms captures our preference for solution gene sets in which the products of transcribing the genes are connected in known human protein-protein interaction networks. Other sources of pairwise gene relationships could be used, for example functional similarity, or regulatory interactions. This network connectivity preference is captured by a term <italic>N</italic>(<italic>A</italic>,<italic>x</italic>) in the objective function, where <italic>A</italic> is the undirected adjacency matrix corresponding to the network, and <italic>x</italic> is the solution gene set. The new term introduces a reward for any two genes in a solution that are connected. Since the solution vector is binary, the additional term can be defined as <inline-formula id="IEq2"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$N(A,x)=-x^{T}Ax=-\sum _{i,j} A_{ij} x_{i} x_{j}$\end{document}</tex-math><mml:math id="M4"><mml:mi>N</mml:mi><mml:mo>(</mml:mo><mml:mi>A</mml:mi><mml:mo>,</mml:mo><mml:mi>x</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:msup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msup><mml:mtext mathvariant="italic">Ax</mml:mtext><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:munder><mml:mrow><mml:mo>∑</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:munder><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mtext mathvariant="italic">ij</mml:mtext></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="12859_2020_3449_Article_IEq2.gif"/></alternatives></inline-formula>. The scaled term <italic>α</italic><italic>N</italic>(<italic>A</italic>,<italic>x</italic>) with nonnegative weight <italic>α</italic> corresponds to providing a reward of <italic>α</italic> every time two genes <italic>i</italic> and <italic>j</italic> present in the solution, that is, with <italic>x</italic><sub><italic>i</italic></sub>=1 and <italic>x</italic><sub><italic>j</italic></sub>=1, are connected by an edge, that is, when <italic>A</italic><sub><italic>ij</italic></sub>=1. The effect of introducing the network term can be seen in Fig. <xref rid="Fig3" ref-type="fig">3</xref>.
<fig id="Fig3"><label>Fig. 3</label><caption><p>Illustration of the role of the network term <italic>N</italic>(<italic>A</italic>,<italic>x</italic>). Based solely on the mutual exclusivity, potential solutions 1 and 2 are equally good, both show perfect mutual exclusivity. Inclusion of network term <italic>N</italic>(<italic>A</italic>,<italic>x</italic>) makes potential solution 2 the preferred one, since it consists of more highly connected genes</p></caption><graphic xlink:href="12859_2020_3449_Fig3_HTML" id="MO3"/></fig></p>
      <p>The second term in the objective function captures mutual exclusivity pattern among solution genes. We use a flexible, quadratic term previously used in our mutual exclusivity method, QuaDMutEx [<xref ref-type="bibr" rid="CR21">21</xref>]. Briefly, the term penalizes for solutions that leave some patients not showing any mutation in the solution genes, as well as for solutions in which patients are covered by more than one mutation. The penalty for excess mutations grows quadratically with the number of mutations over one. The ration of penalty for multiple mutations to penalty for no mutation can be tweaked by parameter <italic>k</italic>. For example, for a slow growing tumor, where there is ample time for additional mutations to accumulate in a single pathway, <italic>k</italic> should be low. In addition, we define parameter <italic>C</italic> to be a penalty incurred by adding one more gene to the solution set.</p>
      <p>For any possible solution vector <italic>x</italic>, the penalty score is a sum of the two terms described above, and is
<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document} $$ {\begin{aligned} L(G,A,x)&amp;=-\alpha x^{T} A x + \sum_{i=1}^{n} \frac{1+k}{2}\left(G_{i} x - 1\right)\left(G_{i} x - \frac{2}{1+k}\right) + C ||x||_{0}. \end{aligned}}  $$ \end{document}</tex-math><mml:math id="M6"><mml:mtable><mml:mtr><mml:mtd><mml:mi>L</mml:mi><mml:mo>(</mml:mo><mml:mi>G</mml:mi><mml:mo>,</mml:mo><mml:mi>A</mml:mi><mml:mo>,</mml:mo><mml:mi>x</mml:mi><mml:mo>)</mml:mo></mml:mtd><mml:mtd><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mi>α</mml:mi><mml:msup><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msup><mml:mtext mathvariant="italic">Ax</mml:mtext><mml:mo>+</mml:mo><mml:munderover><mml:mrow><mml:mo>∑</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:munderover><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:msub><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mi>x</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced><mml:mfenced close=")" open="(" separators=""><mml:mrow><mml:msub><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mi>x</mml:mi><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mi>C</mml:mi><mml:mo>|</mml:mo><mml:mo>|</mml:mo><mml:mi>x</mml:mi><mml:mo>|</mml:mo><mml:msub><mml:mrow><mml:mo>|</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mi>.</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:math><graphic xlink:href="12859_2020_3449_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula></p>
    </sec>
    <sec id="Sec12">
      <title>Algorithm for finding high-quality driver gene sets</title>
      <p>The minimization of the quadratic penalty function <italic>L</italic>(<italic>G</italic>,<italic>A</italic>,<italic>x</italic>) over binary vectors <italic>x</italic> is an example of an unconstrained binary quadratic problem (BQP). While BQPs are known to be NP-hard [<xref ref-type="bibr" rid="CR72">72</xref>], for problems small enough the optimal solution can still be found. For example, for datasets with up to 1000 patients, if one focuses on only <italic>ν</italic>=50 genes, the solution <italic>x</italic> that is the global minimum of <italic>L</italic>(<italic>G</italic>,<italic>A</italic>,<italic>x</italic>) can be found in below a second.</p>
      <p>As we have shown before [<xref ref-type="bibr" rid="CR21">21</xref>], high-quality approximate solutions to BQP problems involving thousands of genes can be found efficiently by an iterative algorithm that maintains an evolving set of size <italic>ν</italic> consisting of candidate driver genes, and in each of the <italic>T</italic> iterations finds an optimal solution to a small instance of the problem in Eq. <xref rid="Equ1" ref-type="">1</xref> involving only the current candidate genes. This allows for improving the quality of the driver gene set, while exploring a diverse set of possible genes as candidates.</p>
      <p>A single run of QuaDMutNetEx will return a set of functionally-related driver genes with high mutual exclusivity and high network connectivity. Running QuaDMutNetEx in sequence, removing discovered genes from input matrices <italic>G</italic> and <italic>A</italic> after each iteration, will allow to uncover genes from multiple pathways needed for oncogenesis, although the joint solution is no longer expected to have high connectivity, nor to conform to the mutual exclusivity pattern.</p>
    </sec>
  </sec>
</body>
<back>
  <glossary>
    <title>Abbreviations</title>
    <def-list>
      <def-item>
        <term>TCGA</term>
        <def>
          <p>The Cancer Genome Atlas</p>
        </def>
      </def-item>
      <def-item>
        <term>TN</term>
        <def>
          <p>Triple negative breast cancer</p>
        </def>
      </def-item>
      <def-item>
        <term>GBM</term>
        <def>
          <p>Glioblastoma multiforme</p>
        </def>
      </def-item>
      <def-item>
        <term>HGS</term>
        <def>
          <p>High-grade serous ovarian cancer</p>
        </def>
      </def-item>
      <def-item>
        <term>COSMIC</term>
        <def>
          <p>Catalogue of somatic mutations in cancer</p>
        </def>
      </def-item>
      <def-item>
        <term>DDBv2</term>
        <def>
          <p>DriverDBv2</p>
        </def>
      </def-item>
    </def-list>
  </glossary>
  <fn-group>
    <fn>
      <p>
        <bold>Publisher’s Note</bold>
      </p>
      <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
    </fn>
  </fn-group>
  <ack>
    <p>The authors thank the development team of Gurobi for providing free, academic license for their optimization software.</p>
  </ack>
  <notes notes-type="author-contribution">
    <title>Authors’ contributions</title>
    <p>YB and TA conceived the method. YB, AA and TA drafted the manuscript. YB implemented the method. YB and TA performed and analyzed the experiments. YB, AA and TA read and approved the final manuscript.</p>
  </notes>
  <notes notes-type="funding-information">
    <title>Funding</title>
    <p>TA is supported by NSF grant IIS-1453658. NSF provided funds for the article processing fee and for the corresponding author’s work on the research presented in this manuscript. The funding agency had no role in study design, in data collection, analysis and interpretation, or in manuscript preparation.</p>
  </notes>
  <notes>
    <title>Ethics approval and consent to participate</title>
    <p>Not applicable.</p>
  </notes>
  <notes>
    <title>Consent for publication</title>
    <p>Not applicable.</p>
  </notes>
  <notes notes-type="COI-statement">
    <title>Competing interests</title>
    <p>The authors declare that they have no competing interests.</p>
  </notes>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bignell</surname>
            <given-names>GR</given-names>
          </name>
          <name>
            <surname>Greenman</surname>
            <given-names>CD</given-names>
          </name>
          <name>
            <surname>Davies</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Butler</surname>
            <given-names>AP</given-names>
          </name>
          <name>
            <surname>Edkins</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Andrews</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Buck</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Beare</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Latimer</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Signatures of mutation and selection in the cancer genome</article-title>
        <source>Nature</source>
        <year>2010</year>
        <volume>463</volume>
        <issue>7283</issue>
        <fpage>893</fpage>
        <lpage>8</lpage>
        <pub-id pub-id-type="doi">10.1038/nature08768</pub-id>
        <?supplied-pmid 20164919?>
        <pub-id pub-id-type="pmid">20164919</pub-id>
      </element-citation>
    </ref>
    <ref id="CR2">
      <label>2</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Knudson</surname>
            <given-names>AG</given-names>
          </name>
        </person-group>
        <article-title>Cancer genetics</article-title>
        <source>Am J Med Genet</source>
        <year>2002</year>
        <volume>111</volume>
        <issue>1</issue>
        <fpage>96</fpage>
        <lpage>102</lpage>
        <pub-id pub-id-type="doi">10.1002/ajmg.10320</pub-id>
        <?supplied-pmid 12124744?>
        <pub-id pub-id-type="pmid">12124744</pub-id>
      </element-citation>
    </ref>
    <ref id="CR3">
      <label>3</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Vogelstein</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Papadopoulos</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Velculescu</surname>
            <given-names>VE</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Diaz</surname>
            <given-names>LA</given-names>
          </name>
          <name>
            <surname>Kinzler</surname>
            <given-names>KW</given-names>
          </name>
        </person-group>
        <article-title>Cancer Genome Landsc</article-title>
        <source>Science</source>
        <year>2013</year>
        <volume>339</volume>
        <issue>6127</issue>
        <fpage>1546</fpage>
        <lpage>58</lpage>
        <pub-id pub-id-type="doi">10.1126/science.1235122</pub-id>
        <?supplied-pmid 23539594?>
        <pub-id pub-id-type="pmid">23539594</pub-id>
      </element-citation>
    </ref>
    <ref id="CR4">
      <label>4</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>McCormick</surname>
            <given-names>F</given-names>
          </name>
        </person-group>
        <article-title>Signalling networks that cause cancer</article-title>
        <source>Trends Biochem Sci</source>
        <year>1999</year>
        <volume>24</volume>
        <issue>12</issue>
        <fpage>53</fpage>
        <lpage>6</lpage>
        <pub-id pub-id-type="doi">10.1016/S0968-0004(99)01480-2</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Vogelstein</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Kinzler</surname>
            <given-names>KW</given-names>
          </name>
        </person-group>
        <article-title>Cancer genes and the pathways they control</article-title>
        <source>Nat Med</source>
        <year>2004</year>
        <volume>10</volume>
        <issue>8</issue>
        <fpage>789</fpage>
        <lpage>99</lpage>
        <pub-id pub-id-type="doi">10.1038/nm1087</pub-id>
        <?supplied-pmid 15286780?>
        <pub-id pub-id-type="pmid">15286780</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yeang</surname>
            <given-names>C-H</given-names>
          </name>
          <name>
            <surname>McCormick</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Levine</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Combinatorial patterns of somatic gene mutations in cancer</article-title>
        <source>FASEB J</source>
        <year>2008</year>
        <volume>22</volume>
        <issue>8</issue>
        <fpage>2605</fpage>
        <lpage>22</lpage>
        <pub-id pub-id-type="doi">10.1096/fj.08-108985</pub-id>
        <?supplied-pmid 18434431?>
        <pub-id pub-id-type="pmid">18434431</pub-id>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tomasetti</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Vogelstein</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Parmigiani</surname>
            <given-names>G</given-names>
          </name>
        </person-group>
        <article-title>Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation</article-title>
        <source>Proc Natl Acad Sci</source>
        <year>2013</year>
        <volume>110</volume>
        <issue>6</issue>
        <fpage>1999</fpage>
        <lpage>2004</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.1221068110</pub-id>
        <?supplied-pmid 23345422?>
        <pub-id pub-id-type="pmid">23345422</pub-id>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Loeb</surname>
            <given-names>LA</given-names>
          </name>
        </person-group>
        <article-title>Human cancers express mutator phenotypes: origin, consequences and targeting</article-title>
        <source>Nat Rev Cancer</source>
        <year>2011</year>
        <volume>11</volume>
        <issue>6</issue>
        <fpage>450</fpage>
        <lpage>457</lpage>
        <pub-id pub-id-type="doi">10.1038/nrc3063</pub-id>
        <?supplied-pmid 21593786?>
        <pub-id pub-id-type="pmid">21593786</pub-id>
      </element-citation>
    </ref>
    <ref id="CR9">
      <label>9</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kennedy</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Schultz</surname>
            <given-names>EM</given-names>
          </name>
          <name>
            <surname>Chappell</surname>
            <given-names>TM</given-names>
          </name>
          <name>
            <surname>Kohrn</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Knowels</surname>
            <given-names>GM</given-names>
          </name>
          <name>
            <surname>Herr</surname>
            <given-names>AJ</given-names>
          </name>
        </person-group>
        <article-title>Volatility of mutator phenotypes at single cell resolution</article-title>
        <source>PLoS Genet</source>
        <year>2015</year>
        <volume>11</volume>
        <issue>4</issue>
        <fpage>1005151</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pgen.1005151</pub-id>
      </element-citation>
    </ref>
    <ref id="CR10">
      <label>10</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Weinstein</surname>
            <given-names>JN</given-names>
          </name>
          <name>
            <surname>Collisson</surname>
            <given-names>EA</given-names>
          </name>
          <name>
            <surname>Mills</surname>
            <given-names>GB</given-names>
          </name>
          <name>
            <surname>Shaw</surname>
            <given-names>KRM</given-names>
          </name>
          <name>
            <surname>Ozenberger</surname>
            <given-names>BA</given-names>
          </name>
          <name>
            <surname>Ellrott</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Shmulevich</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Sander</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Stuart</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Network</surname>
            <given-names>CGAR</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The Cancer Genome Atlas Pan-Cancer analysis project</article-title>
        <source>Nat Genet</source>
        <year>2013</year>
        <volume>45</volume>
        <issue>10</issue>
        <fpage>1113</fpage>
        <lpage>20</lpage>
        <pub-id pub-id-type="doi">10.1038/ng.2764</pub-id>
        <?supplied-pmid 24071849?>
        <pub-id pub-id-type="pmid">24071849</pub-id>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kandoth</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>McLellan</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Vandin</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Ye</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Niu</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Xie</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>McMichael</surname>
            <given-names>JF</given-names>
          </name>
          <name>
            <surname>Wyczalkowski</surname>
            <given-names>MA</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Mutational landscape and significance across 12 major cancer types</article-title>
        <source>Nature</source>
        <year>2013</year>
        <volume>502</volume>
        <issue>7471</issue>
        <fpage>333</fpage>
        <lpage>9</lpage>
        <pub-id pub-id-type="doi">10.1038/nature12634</pub-id>
        <?supplied-pmid 24132290?>
        <pub-id pub-id-type="pmid">24132290</pub-id>
      </element-citation>
    </ref>
    <ref id="CR12">
      <label>12</label>
      <mixed-citation publication-type="other">Dimitrakopoulos CM, Beerenwinkel N. Computational approaches for the identification of cancer genes and pathways. Wiley Interdiscip Rev Syst Biol Med. 2017; 9(1). 10.1002/wsbm.1364.</mixed-citation>
    </ref>
    <ref id="CR13">
      <label>13</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ding</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Wendl</surname>
            <given-names>MC</given-names>
          </name>
          <name>
            <surname>McMichael</surname>
            <given-names>JF</given-names>
          </name>
          <name>
            <surname>Raphael</surname>
            <given-names>BJ</given-names>
          </name>
        </person-group>
        <article-title>Expanding the computational toolbox for mining cancer genomes</article-title>
        <source>Nat Rev Genet</source>
        <year>2014</year>
        <volume>15</volume>
        <issue>8</issue>
        <fpage>556</fpage>
        <pub-id pub-id-type="doi">10.1038/nrg3767</pub-id>
        <?supplied-pmid 25001846?>
        <pub-id pub-id-type="pmid">25001846</pub-id>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Shen</surname>
            <given-names>B</given-names>
          </name>
        </person-group>
        <article-title>Deciphering oncogenic drivers: from single genes to integrated pathways</article-title>
        <source>Brief Bioinforma</source>
        <year>2014</year>
        <volume>16</volume>
        <issue>3</issue>
        <fpage>413</fpage>
        <lpage>28</lpage>
        <pub-id pub-id-type="doi">10.1093/bib/bbu039</pub-id>
      </element-citation>
    </ref>
    <ref id="CR15">
      <label>15</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Vandin</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Upfal</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Raphael</surname>
            <given-names>BJ</given-names>
          </name>
        </person-group>
        <article-title>De novo discovery of mutated driver pathways in cancer</article-title>
        <source>Genome Res</source>
        <year>2012</year>
        <volume>22</volume>
        <issue>2</issue>
        <fpage>375</fpage>
        <lpage>85</lpage>
        <pub-id pub-id-type="doi">10.1101/gr.120477.111</pub-id>
        <?supplied-pmid 21653252?>
        <pub-id pub-id-type="pmid">21653252</pub-id>
      </element-citation>
    </ref>
    <ref id="CR16">
      <label>16</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Leiserson</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Blokh</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Sharan</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Raphael</surname>
            <given-names>BJ</given-names>
          </name>
        </person-group>
        <article-title>Simultaneous identification of multiple driver pathways in cancer</article-title>
        <source>PLoS Comput Biol</source>
        <year>2013</year>
        <volume>9</volume>
        <issue>5</issue>
        <fpage>1003054</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pcbi.1003054</pub-id>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Miller</surname>
            <given-names>CA</given-names>
          </name>
          <name>
            <surname>Settle</surname>
            <given-names>SH</given-names>
          </name>
          <name>
            <surname>Sulman</surname>
            <given-names>EP</given-names>
          </name>
          <name>
            <surname>Aldape</surname>
            <given-names>KD</given-names>
          </name>
          <name>
            <surname>Milosavljevic</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Discovering functional modules by identifying recurrent and mutually exclusive mutational patterns in tumors</article-title>
        <source>BMC Med Genom</source>
        <year>2011</year>
        <volume>4</volume>
        <issue>1</issue>
        <fpage>1</fpage>
        <pub-id pub-id-type="doi">10.1186/1755-8794-4-34</pub-id>
      </element-citation>
    </ref>
    <ref id="CR18">
      <label>18</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Leiserson</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>H-T</given-names>
          </name>
          <name>
            <surname>Vandin</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Raphael</surname>
            <given-names>BJ</given-names>
          </name>
        </person-group>
        <article-title>CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer</article-title>
        <source>Genome Biol</source>
        <year>2015</year>
        <volume>16</volume>
        <issue>1</issue>
        <fpage>1</fpage>
        <pub-id pub-id-type="doi">10.1186/s13059-015-0700-7</pub-id>
        <pub-id pub-id-type="pmid">25583448</pub-id>
      </element-citation>
    </ref>
    <ref id="CR19">
      <label>19</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Constantinescu</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Szczurek</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Mohammadi</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Rahnenführer</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Beerenwinkel</surname>
            <given-names>N</given-names>
          </name>
        </person-group>
        <article-title>TiMEx: a waiting time model for mutually exclusive cancer alterations</article-title>
        <source>Bioinformatics</source>
        <year>2015</year>
        <volume>32</volume>
        <issue>7</issue>
        <fpage>968</fpage>
        <lpage>75</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btv400</pub-id>
        <?supplied-pmid 26163509?>
        <pub-id pub-id-type="pmid">26163509</pub-id>
      </element-citation>
    </ref>
    <ref id="CR20">
      <label>20</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ciriello</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Cerami</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Sander</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Schultz</surname>
            <given-names>N</given-names>
          </name>
        </person-group>
        <article-title>Mutual exclusivity analysis identifies oncogenic network modules</article-title>
        <source>Genome Res</source>
        <year>2012</year>
        <volume>22</volume>
        <issue>2</issue>
        <fpage>398</fpage>
        <lpage>406</lpage>
        <pub-id pub-id-type="doi">10.1101/gr.125567.111</pub-id>
        <?supplied-pmid 21908773?>
        <pub-id pub-id-type="pmid">21908773</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bokhari</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Arodz</surname>
            <given-names>T</given-names>
          </name>
        </person-group>
        <article-title>QuaDMutEx: quadratic driver mutation explorer</article-title>
        <source>BMC Bioinformatics</source>
        <year>2017</year>
        <volume>18</volume>
        <issue>1</issue>
        <fpage>458</fpage>
        <pub-id pub-id-type="doi">10.1186/s12859-017-1869-4</pub-id>
        <?supplied-pmid 29065872?>
        <pub-id pub-id-type="pmid">29065872</pub-id>
      </element-citation>
    </ref>
    <ref id="CR22">
      <label>22</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Vandin</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Upfal</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Raphael</surname>
            <given-names>BJ</given-names>
          </name>
        </person-group>
        <article-title>Algorithms for detecting significantly mutated pathways in cancer</article-title>
        <source>J Comput Biol</source>
        <year>2011</year>
        <volume>18</volume>
        <issue>3</issue>
        <fpage>507</fpage>
        <lpage>22</lpage>
        <pub-id pub-id-type="doi">10.1089/cmb.2010.0265</pub-id>
        <?supplied-pmid 21385051?>
        <pub-id pub-id-type="pmid">21385051</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Leiserson</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Vandin</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>H-T</given-names>
          </name>
          <name>
            <surname>Dobson</surname>
            <given-names>JR</given-names>
          </name>
          <name>
            <surname>Eldridge</surname>
            <given-names>JV</given-names>
          </name>
          <name>
            <surname>Thomas</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Papoutsaki</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Niu</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>McLellan</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes</article-title>
        <source>Nat Genet</source>
        <year>2015</year>
        <volume>47</volume>
        <issue>2</issue>
        <fpage>106</fpage>
        <lpage>14</lpage>
        <pub-id pub-id-type="doi">10.1038/ng.3168</pub-id>
        <?supplied-pmid 25501392?>
        <pub-id pub-id-type="pmid">25501392</pub-id>
      </element-citation>
    </ref>
    <ref id="CR24">
      <label>24</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bashashati</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Haffari</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Ding</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Ha</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Lui</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Rosner</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Huntsman</surname>
            <given-names>DG</given-names>
          </name>
          <name>
            <surname>Caldas</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Aparicio</surname>
            <given-names>SA</given-names>
          </name>
          <name>
            <surname>Shah</surname>
            <given-names>SP</given-names>
          </name>
        </person-group>
        <article-title>DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer</article-title>
        <source>Genome Biol</source>
        <year>2012</year>
        <volume>13</volume>
        <issue>12</issue>
        <fpage>124</fpage>
        <pub-id pub-id-type="doi">10.1186/gb-2012-13-12-r124</pub-id>
      </element-citation>
    </ref>
    <ref id="CR25">
      <label>25</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lawrence</surname>
            <given-names>MS</given-names>
          </name>
          <name>
            <surname>Stojanov</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Polak</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Kryukov</surname>
            <given-names>GV</given-names>
          </name>
          <name>
            <surname>Cibulskis</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Sivachenko</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Carter</surname>
            <given-names>SL</given-names>
          </name>
          <name>
            <surname>Stewart</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Mermel</surname>
            <given-names>CH</given-names>
          </name>
          <name>
            <surname>Roberts</surname>
            <given-names>SA</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Mutational heterogeneity in cancer and the search for new cancer-associated genes</article-title>
        <source>Nature</source>
        <year>2013</year>
        <volume>499</volume>
        <issue>7457</issue>
        <fpage>214</fpage>
        <lpage>8</lpage>
        <pub-id pub-id-type="doi">10.1038/nature12213</pub-id>
        <?supplied-pmid 3919509?>
        <pub-id pub-id-type="pmid">23770567</pub-id>
      </element-citation>
    </ref>
    <ref id="CR26">
      <label>26</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tate</surname>
            <given-names>JG</given-names>
          </name>
          <name>
            <surname>Bamford</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Jubb</surname>
            <given-names>HC</given-names>
          </name>
          <name>
            <surname>Sondka</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Beare</surname>
            <given-names>DM</given-names>
          </name>
          <name>
            <surname>Bindal</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Boutselakis</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Cole</surname>
            <given-names>CG</given-names>
          </name>
          <name>
            <surname>Creatore</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Dawson</surname>
            <given-names>E</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Cosmic: the catalogue of somatic mutations in cancer</article-title>
        <source>Nucleic Acids Res</source>
        <year>2018</year>
        <volume>47</volume>
        <issue>D1</issue>
        <fpage>941</fpage>
        <lpage>7</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gky1015</pub-id>
      </element-citation>
    </ref>
    <ref id="CR27">
      <label>27</label>
      <mixed-citation publication-type="other">cancer.sanger.ac.uk. Accessed 14 Dec 2019.</mixed-citation>
    </ref>
    <ref id="CR28">
      <label>28</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chung</surname>
            <given-names>I-F</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>C-Y</given-names>
          </name>
          <name>
            <surname>Su</surname>
            <given-names>S-C</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>C-Y</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>K-J</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>H-W</given-names>
          </name>
          <name>
            <surname>Cheng</surname>
            <given-names>W-C</given-names>
          </name>
        </person-group>
        <article-title>DriverDBv2: a database for human cancer driver gene research</article-title>
        <source>Nucleic Acids Res</source>
        <year>2016</year>
        <volume>44</volume>
        <issue>D1</issue>
        <fpage>975</fpage>
        <lpage>9</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkv1314</pub-id>
      </element-citation>
    </ref>
    <ref id="CR29">
      <label>29</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chin</surname>
            <given-names>SF</given-names>
          </name>
          <name>
            <surname>Teschendorff</surname>
            <given-names>AE</given-names>
          </name>
          <name>
            <surname>Marioni</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Barbosa-Morais</surname>
            <given-names>NL</given-names>
          </name>
          <name>
            <surname>Thorne</surname>
            <given-names>NP</given-names>
          </name>
          <name>
            <surname>Costa</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Pinder</surname>
            <given-names>SE</given-names>
          </name>
          <name>
            <surname>van De Wiel</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Green</surname>
            <given-names>AR</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer</article-title>
        <source>Genome Biol</source>
        <year>2007</year>
        <volume>8</volume>
        <issue>10</issue>
        <fpage>215</fpage>
        <pub-id pub-id-type="doi">10.1186/gb-2007-8-10-r215</pub-id>
        <pub-id pub-id-type="pmid">17543136</pub-id>
      </element-citation>
    </ref>
    <ref id="CR30">
      <label>30</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Duex</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>Swain</surname>
            <given-names>KE</given-names>
          </name>
          <name>
            <surname>Dancik</surname>
            <given-names>GM</given-names>
          </name>
          <name>
            <surname>Paucek</surname>
            <given-names>RD</given-names>
          </name>
          <name>
            <surname>Owens</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Churchill</surname>
            <given-names>ME</given-names>
          </name>
          <name>
            <surname>Theodorescu</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>Functional impact of chromatin remodeling gene mutations and predictive signature for therapeutic response in bladder cancer</article-title>
        <source>Mol Cancer Res</source>
        <year>2018</year>
        <volume>16</volume>
        <issue>1</issue>
        <fpage>69</fpage>
        <lpage>77</lpage>
        <pub-id pub-id-type="doi">10.1158/1541-7786.MCR-17-0260</pub-id>
        <pub-id pub-id-type="pmid">28970362</pub-id>
      </element-citation>
    </ref>
    <ref id="CR31">
      <label>31</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yadav</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Masroor</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Nandi</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Kaza</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Jain</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Khurana</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Saxena</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Promoter methylation of BRCA1, DAPK1 and RASSF1A is associated with increased mortality among indian women with breast cancer</article-title>
        <source>Asian Pac J Cancer Prev APJCP</source>
        <year>2018</year>
        <volume>19</volume>
        <issue>2</issue>
        <fpage>443</fpage>
        <?supplied-pmid 29480000?>
        <pub-id pub-id-type="pmid">29480000</pub-id>
      </element-citation>
    </ref>
    <ref id="CR32">
      <label>32</label>
      <mixed-citation publication-type="other">Qin R, Wolfenson H, Saxena M, Sheetz M. Tumor suppressor DAPK1 catalyzes adhesion assembly on rigid but anoikis on soft matrices. bioRxiv. 2018:320739. 10.1101/320739.</mixed-citation>
    </ref>
    <ref id="CR33">
      <label>33</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Qin</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Ma</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Liao</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Jiang</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>NCOA1 promotes angiogenesis in breast tumors by simultaneously enhancing both HIF1 <italic>α</italic>- and AP-1-mediated VEGFa transcription</article-title>
        <source>Oncotarget</source>
        <year>2015</year>
        <volume>6</volume>
        <issue>27</issue>
        <fpage>23890</fpage>
        <pub-id pub-id-type="doi">10.18632/oncotarget.4341</pub-id>
        <?supplied-pmid 4695159?>
        <pub-id pub-id-type="pmid">26287601</pub-id>
      </element-citation>
    </ref>
    <ref id="CR34">
      <label>34</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ventura-Bixenshpaner</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Asraf</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Chakraborty</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Elkabets</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Sekler</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Taylor</surname>
            <given-names>KM</given-names>
          </name>
          <name>
            <surname>Hershfinkel</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Enhanced ZnR/GPR39 activity in breast cancer, an alternative trigger of signaling leading to cell growth</article-title>
        <source>Sci Rep</source>
        <year>2018</year>
        <volume>8</volume>
        <issue>1</issue>
        <fpage>8119</fpage>
        <pub-id pub-id-type="doi">10.1038/s41598-018-26459-5</pub-id>
        <?supplied-pmid 5970167?>
        <pub-id pub-id-type="pmid">29802348</pub-id>
      </element-citation>
    </ref>
    <ref id="CR35">
      <label>35</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bonuccelli</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Tsirigos</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Whitaker-Menezes</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Pavlides</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Pestell</surname>
            <given-names>RG</given-names>
          </name>
          <name>
            <surname>Chiavarina</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Frank</surname>
            <given-names>PG</given-names>
          </name>
          <name>
            <surname>Flomenberg</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Howell</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Martinez-Outschoorn</surname>
            <given-names>UE</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism</article-title>
        <source>Cell Cycle</source>
        <year>2010</year>
        <volume>9</volume>
        <issue>17</issue>
        <fpage>3506</fpage>
        <lpage>514</lpage>
        <pub-id pub-id-type="doi">10.4161/cc.9.17.12731</pub-id>
        <?supplied-pmid 3047616?>
        <pub-id pub-id-type="pmid">20818174</pub-id>
      </element-citation>
    </ref>
    <ref id="CR36">
      <label>36</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cai</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Nogales-Cadenas</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>J-R</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>O’Brien</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Montagna</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>ZD</given-names>
          </name>
        </person-group>
        <article-title>Transcriptomic dynamics of breast cancer progression in the MMTV-PyMT mouse model</article-title>
        <source>BMC Genomics</source>
        <year>2017</year>
        <volume>18</volume>
        <issue>1</issue>
        <fpage>185</fpage>
        <pub-id pub-id-type="doi">10.1186/s12864-017-3563-3</pub-id>
        <?supplied-pmid 5316186?>
        <pub-id pub-id-type="pmid">28212608</pub-id>
      </element-citation>
    </ref>
    <ref id="CR37">
      <label>37</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yan-Fang</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Zhi-Heng</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Li-Xiao</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Fang</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Jun</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Gang</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Lan</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Na-Na</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Xiao-Juan</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Li-Chao</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Molecular mechanism of the cell death induced by the histone deacetylase pan inhibitor LBH589 (panobinostat) in wilms tumor cells</article-title>
        <source>PloS ONE</source>
        <year>2015</year>
        <volume>10</volume>
        <issue>7</issue>
        <fpage>0126566</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0126566</pub-id>
      </element-citation>
    </ref>
    <ref id="CR38">
      <label>38</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chiavarina</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Whitaker-Menezes</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Migneco</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Martinez-Outschoorn</surname>
            <given-names>UE</given-names>
          </name>
          <name>
            <surname>Pavlides</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Howell</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Tanowitz</surname>
            <given-names>HB</given-names>
          </name>
          <name>
            <surname>Casimiro</surname>
            <given-names>MC</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Pestell</surname>
            <given-names>RG</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>HIF1-alpha functions as a tumor promoter in cancer-associated fibroblasts, and as a tumor suppressor in breast cancer cells: autophagy drives compartment-specific oncogenesis</article-title>
        <source>Cell Cycle</source>
        <year>2010</year>
        <volume>9</volume>
        <issue>17</issue>
        <fpage>3534</fpage>
        <lpage>51</lpage>
        <pub-id pub-id-type="doi">10.4161/cc.9.17.12908</pub-id>
        <?supplied-pmid 3047618?>
        <pub-id pub-id-type="pmid">20864819</pub-id>
      </element-citation>
    </ref>
    <ref id="CR39">
      <label>39</label>
      <mixed-citation publication-type="other">Ponente M, Campanini L, Cuttano R, Piunti A, Delledonne GA, Coltella N, Valsecchi R, Villa A, Cavallaro U, Pattini L, et al.PML promotes metastasis of triple-negative breast cancer through transcriptional regulation of HIF1A target genes. JCI Insight. 2017; 2(4). 10.1172/jci.insight.87380.</mixed-citation>
    </ref>
    <ref id="CR40">
      <label>40</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ssempala</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Vaccine targeting HIF1A in triple negative breast cancer</article-title>
        <source>Eur J Cancer</source>
        <year>2017</year>
        <volume>72</volume>
        <fpage>26</fpage>
        <pub-id pub-id-type="doi">10.1016/S0959-8049(17)30164-8</pub-id>
      </element-citation>
    </ref>
    <ref id="CR41">
      <label>41</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rao</surname>
            <given-names>RC</given-names>
          </name>
          <name>
            <surname>Dou</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <article-title>Hijacked in cancer: the KMT2 (MLL) family of methyltransferases</article-title>
        <source>Nat Rev Cancer</source>
        <year>2015</year>
        <volume>15</volume>
        <issue>6</issue>
        <fpage>334</fpage>
        <pub-id pub-id-type="doi">10.1038/nrc3929</pub-id>
        <?supplied-pmid 25998713?>
        <pub-id pub-id-type="pmid">25998713</pub-id>
      </element-citation>
    </ref>
    <ref id="CR42">
      <label>42</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Palacios</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Gamallo</surname>
            <given-names>C</given-names>
          </name>
        </person-group>
        <article-title>Mutations in the <italic>β</italic>-catenin gene (CTNNB1) in endometrioid ovarian carcinomas</article-title>
        <source>Cancer Res</source>
        <year>1998</year>
        <volume>58</volume>
        <issue>7</issue>
        <fpage>1344</fpage>
        <lpage>7</lpage>
        <?supplied-pmid 9537226?>
        <pub-id pub-id-type="pmid">9537226</pub-id>
      </element-citation>
    </ref>
    <ref id="CR43">
      <label>43</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pathak</surname>
            <given-names>HB</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Sethi</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Hirst</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Schilder</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Golemis</surname>
            <given-names>EA</given-names>
          </name>
          <name>
            <surname>Godwin</surname>
            <given-names>AK</given-names>
          </name>
        </person-group>
        <article-title>A synthetic lethality screen using a focused siRNA library to identify sensitizers to dasatinib therapy for the treatment of epithelial ovarian cancer</article-title>
        <source>PloS ONE</source>
        <year>2015</year>
        <volume>10</volume>
        <issue>12</issue>
        <fpage>0144126</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0144126</pub-id>
      </element-citation>
    </ref>
    <ref id="CR44">
      <label>44</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sethi</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Pathak</surname>
            <given-names>HB</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Einarson</surname>
            <given-names>MB</given-names>
          </name>
          <name>
            <surname>Vathipadiekal</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Gunewardena</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Birrer</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Godwin</surname>
            <given-names>AK</given-names>
          </name>
        </person-group>
        <article-title>An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer</article-title>
        <source>PLoS ONE</source>
        <year>2012</year>
        <volume>7</volume>
        <issue>10</issue>
        <fpage>47086</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0047086</pub-id>
      </element-citation>
    </ref>
    <ref id="CR45">
      <label>45</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Revillion</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Bonneterre</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Peyrat</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>ERBB2 oncogene in human breast cancer and its clinical significance</article-title>
        <source>Eur J Cancer</source>
        <year>1998</year>
        <volume>34</volume>
        <issue>6</issue>
        <fpage>791</fpage>
        <lpage>808</lpage>
        <pub-id pub-id-type="doi">10.1016/S0959-8049(97)10157-5</pub-id>
        <?supplied-pmid 9797688?>
        <pub-id pub-id-type="pmid">9797688</pub-id>
      </element-citation>
    </ref>
    <ref id="CR46">
      <label>46</label>
      <mixed-citation publication-type="other">Bonomi S, Gallo S, Catillo M, Pignataro D, Biamonti G, Ghigna C. Oncogenic alternative splicing switches: role in cancer progression and prospects for therapy. Int J Cell Biol. 2013; 2013. 10.1155/2013/962038.</mixed-citation>
    </ref>
    <ref id="CR47">
      <label>47</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Mo</surname>
            <given-names>JQ</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Dong</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer</article-title>
        <source>BMC Cancer</source>
        <year>2008</year>
        <volume>8</volume>
        <issue>1</issue>
        <fpage>158</fpage>
        <pub-id pub-id-type="doi">10.1186/1471-2407-8-158</pub-id>
        <?supplied-pmid 18518979?>
        <pub-id pub-id-type="pmid">18518979</pub-id>
      </element-citation>
    </ref>
    <ref id="CR48">
      <label>48</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jaiswal</surname>
            <given-names>BS</given-names>
          </name>
          <name>
            <surname>Kljavin</surname>
            <given-names>NM</given-names>
          </name>
          <name>
            <surname>Stawiski</surname>
            <given-names>EW</given-names>
          </name>
          <name>
            <surname>Chan</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Parikh</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Durinck</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Chaudhuri</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Pujara</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Guillory</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Edgar</surname>
            <given-names>KA</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Oncogenic ERBB3 mutations in human cancers</article-title>
        <source>Cancer Cell</source>
        <year>2013</year>
        <volume>23</volume>
        <issue>5</issue>
        <fpage>603</fpage>
        <lpage>17</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ccr.2013.04.012</pub-id>
        <?supplied-pmid 23680147?>
        <pub-id pub-id-type="pmid">23680147</pub-id>
      </element-citation>
    </ref>
    <ref id="CR49">
      <label>49</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jones</surname>
            <given-names>DT</given-names>
          </name>
          <name>
            <surname>Hutter</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Jäger</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Korshunov</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kool</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Warnatz</surname>
            <given-names>H-J</given-names>
          </name>
          <name>
            <surname>Zichner</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Lambert</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Ryzhova</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Quang</surname>
            <given-names>DAK</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma</article-title>
        <source>Nat Genet</source>
        <year>2013</year>
        <volume>45</volume>
        <issue>8</issue>
        <fpage>927</fpage>
        <pub-id pub-id-type="doi">10.1038/ng.2682</pub-id>
        <?supplied-pmid 23817572?>
        <pub-id pub-id-type="pmid">23817572</pub-id>
      </element-citation>
    </ref>
    <ref id="CR50">
      <label>50</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sakai</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Ukita</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Schmidt</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>De Velasco</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Roter</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Jevons</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Nishio</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Mandai</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status</article-title>
        <source>Cancer Lett</source>
        <year>2017</year>
        <volume>405</volume>
        <fpage>22</fpage>
        <lpage>8</lpage>
        <pub-id pub-id-type="doi">10.1016/j.canlet.2017.07.013</pub-id>
        <?supplied-pmid 28734796?>
        <pub-id pub-id-type="pmid">28734796</pub-id>
      </element-citation>
    </ref>
    <ref id="CR51">
      <label>51</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Naderi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Teschendorff</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Barbosa-Morais</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Pinder</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Green</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Powe</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Robertson</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Aparicio</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Ellis</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Brenton</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A gene-expression signature to predict survival in breast cancer across independent data sets</article-title>
        <source>Oncogene</source>
        <year>2007</year>
        <volume>26</volume>
        <issue>10</issue>
        <fpage>1507</fpage>
        <pub-id pub-id-type="doi">10.1038/sj.onc.1209920</pub-id>
        <?supplied-pmid 16936776?>
        <pub-id pub-id-type="pmid">16936776</pub-id>
      </element-citation>
    </ref>
    <ref id="CR52">
      <label>52</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Giubellino</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Burke</surname>
            <given-names>TR</given-names>
          </name>
          <name>
            <surname>Bottaro</surname>
            <given-names>DP</given-names>
          </name>
        </person-group>
        <article-title>Grb2 signaling in cell motility and cancer</article-title>
        <source>Expert Opin Ther Targets</source>
        <year>2008</year>
        <volume>12</volume>
        <issue>8</issue>
        <fpage>1021</fpage>
        <lpage>33</lpage>
        <pub-id pub-id-type="doi">10.1517/14728222.12.8.1021</pub-id>
        <?supplied-pmid 18620523?>
        <pub-id pub-id-type="pmid">18620523</pub-id>
      </element-citation>
    </ref>
    <ref id="CR53">
      <label>53</label>
      <mixed-citation publication-type="other">Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, et al.High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 2011; 11. 10.1158/2159-8290.cd-11-0039.</mixed-citation>
    </ref>
    <ref id="CR54">
      <label>54</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>W-L</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>T-Y</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>S-W</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>F-J</given-names>
          </name>
          <name>
            <surname>Luo</surname>
            <given-names>C-W</given-names>
          </name>
        </person-group>
        <article-title>Thyrostimulin-TSHR signaling promotes the proliferation of NIH: OVCAR-3 ovarian cancer cells via trans-regulation of the EGFR pathway</article-title>
        <source>Sci Rep</source>
        <year>2016</year>
        <volume>6</volume>
        <fpage>27471</fpage>
        <pub-id pub-id-type="doi">10.1038/srep27471</pub-id>
        <?supplied-pmid 27273257?>
        <pub-id pub-id-type="pmid">27273257</pub-id>
      </element-citation>
    </ref>
    <ref id="CR55">
      <label>55</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chu</surname>
            <given-names>S. -h.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Y. -w.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Shi</surname>
            <given-names>J. -z.</given-names>
          </name>
        </person-group>
        <article-title>Regulation of survival and chemoresistance by HSP90AA1 in ovarian cancer SKOV3 cells</article-title>
        <source>Mol Biol Rep</source>
        <year>2013</year>
        <volume>40</volume>
        <issue>1</issue>
        <fpage>1</fpage>
        <lpage>6</lpage>
        <pub-id pub-id-type="doi">10.1007/s11033-012-1930-3</pub-id>
        <?supplied-pmid 23135731?>
        <pub-id pub-id-type="pmid">23135731</pub-id>
      </element-citation>
    </ref>
    <ref id="CR56">
      <label>56</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yin</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>L</given-names>
          </name>
        </person-group>
        <article-title>Tumor suppressor genes associated with drug resistance in ovarian cancer</article-title>
        <source>Oncol Rep</source>
        <year>2013</year>
        <volume>30</volume>
        <issue>1</issue>
        <fpage>3</fpage>
        <lpage>10</lpage>
        <pub-id pub-id-type="doi">10.3892/or.2013.2446</pub-id>
        <?supplied-pmid 23660957?>
        <pub-id pub-id-type="pmid">23660957</pub-id>
      </element-citation>
    </ref>
    <ref id="CR57">
      <label>57</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ayyildiz</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Gov</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Sinha</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Arga</surname>
            <given-names>KY</given-names>
          </name>
        </person-group>
        <article-title>Ovarian cancer differential interactome and network entropy analysis reveal new candidate biomarkers</article-title>
        <source>Omics: J Integr Biol</source>
        <year>2017</year>
        <volume>21</volume>
        <issue>5</issue>
        <fpage>285</fpage>
        <lpage>94</lpage>
        <pub-id pub-id-type="doi">10.1089/omi.2017.0010</pub-id>
      </element-citation>
    </ref>
    <ref id="CR58">
      <label>58</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wrzeszczynski</surname>
            <given-names>KO</given-names>
          </name>
          <name>
            <surname>Varadan</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Byrnes</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Lum</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Kamalakaran</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Levine</surname>
            <given-names>DA</given-names>
          </name>
          <name>
            <surname>Dimitrova</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>MQ</given-names>
          </name>
          <name>
            <surname>Lucito</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <article-title>Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer</article-title>
        <source>PloS ONE</source>
        <year>2011</year>
        <volume>6</volume>
        <issue>12</issue>
        <fpage>28503</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0028503</pub-id>
      </element-citation>
    </ref>
    <ref id="CR59">
      <label>59</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>S-H</given-names>
          </name>
          <name>
            <surname>Ezhilarasan</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Phillips</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Gallego-Perez</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Sparks</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Taylor</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Ladner</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Furuta</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Sabit</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Chhipa</surname>
            <given-names>R</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Serine/threonine kinase MLK4 determines mesenchymal identity in glioma stem cells in an NF- <italic>κ</italic>B-dependent manner</article-title>
        <source>Cancer Cell</source>
        <year>2016</year>
        <volume>29</volume>
        <issue>2</issue>
        <fpage>201</fpage>
        <lpage>13</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ccell.2016.01.005</pub-id>
        <?supplied-pmid 26859459?>
        <pub-id pub-id-type="pmid">26859459</pub-id>
      </element-citation>
    </ref>
    <ref id="CR60">
      <label>60</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Schiebe</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Ohneseit</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Hoffmann</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Meyermann</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Rodemann</surname>
            <given-names>H-P</given-names>
          </name>
          <name>
            <surname>Bamberg</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors</article-title>
        <source>J Neuro-Oncol</source>
        <year>2000</year>
        <volume>49</volume>
        <issue>3</issue>
        <fpage>197</fpage>
        <lpage>203</lpage>
        <pub-id pub-id-type="doi">10.1023/A:1006410702284</pub-id>
      </element-citation>
    </ref>
    <ref id="CR61">
      <label>61</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zheng</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Lang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Cui</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Jiang</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Gao</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Tian</surname>
            <given-names>W</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Structure of human MDM2 complexed with RPL11 reveals the molecular basis of p53 activation</article-title>
        <source>Genes Dev</source>
        <year>2015</year>
        <volume>29</volume>
        <issue>14</issue>
        <fpage>1524</fpage>
        <lpage>34</lpage>
        <pub-id pub-id-type="doi">10.1101/gad.261792.115</pub-id>
        <?supplied-pmid 26220995?>
        <pub-id pub-id-type="pmid">26220995</pub-id>
      </element-citation>
    </ref>
    <ref id="CR62">
      <label>62</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wehde</surname>
            <given-names>BL</given-names>
          </name>
          <name>
            <surname>Rädler</surname>
            <given-names>PD</given-names>
          </name>
          <name>
            <surname>Shrestha</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Johnson</surname>
            <given-names>SJ</given-names>
          </name>
          <name>
            <surname>Triplett</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Wagner</surname>
            <given-names>K-U</given-names>
          </name>
        </person-group>
        <article-title>Janus kinase 1 plays a critical role in mammary cancer progression</article-title>
        <source>Cell Rep</source>
        <year>2018</year>
        <volume>25</volume>
        <issue>8</issue>
        <fpage>2192</fpage>
        <lpage>207</lpage>
        <pub-id pub-id-type="doi">10.1016/j.celrep.2018.10.063</pub-id>
        <?supplied-pmid 30463015?>
        <pub-id pub-id-type="pmid">30463015</pub-id>
      </element-citation>
    </ref>
    <ref id="CR63">
      <label>63</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hardy</surname>
            <given-names>KM</given-names>
          </name>
          <name>
            <surname>Booth</surname>
            <given-names>BW</given-names>
          </name>
          <name>
            <surname>Hendrix</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Salomon</surname>
            <given-names>DS</given-names>
          </name>
          <name>
            <surname>Strizzi</surname>
            <given-names>L</given-names>
          </name>
        </person-group>
        <article-title>ErbB/EGF signaling and EMT in mammary development and breast cancer</article-title>
        <source>J Mammary Gland Biol Neoplasia</source>
        <year>2010</year>
        <volume>15</volume>
        <issue>2</issue>
        <fpage>191</fpage>
        <lpage>9</lpage>
        <pub-id pub-id-type="doi">10.1007/s10911-010-9172-2</pub-id>
        <?supplied-pmid 20369376?>
        <pub-id pub-id-type="pmid">20369376</pub-id>
      </element-citation>
    </ref>
    <ref id="CR64">
      <label>64</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bhowmick</surname>
            <given-names>DA</given-names>
          </name>
          <name>
            <surname>Zhuang</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Wait</surname>
            <given-names>SD</given-names>
          </name>
          <name>
            <surname>Weil</surname>
            <given-names>RJ</given-names>
          </name>
        </person-group>
        <article-title>A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease</article-title>
        <source>Cancer Res</source>
        <year>2004</year>
        <volume>64</volume>
        <issue>4</issue>
        <fpage>1220</fpage>
        <lpage>3</lpage>
        <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-3137</pub-id>
        <?supplied-pmid 14973082?>
        <pub-id pub-id-type="pmid">14973082</pub-id>
      </element-citation>
    </ref>
    <ref id="CR65">
      <label>65</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Philp</surname>
            <given-names>AJ</given-names>
          </name>
          <name>
            <surname>Campbell</surname>
            <given-names>IG</given-names>
          </name>
          <name>
            <surname>Leet</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Vincan</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Rockman</surname>
            <given-names>SP</given-names>
          </name>
          <name>
            <surname>Whitehead</surname>
            <given-names>RH</given-names>
          </name>
          <name>
            <surname>Thomas</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Phillips</surname>
            <given-names>WA</given-names>
          </name>
        </person-group>
        <article-title>The phosphatidylinositol 3’-kinase p85alpha gene is an oncogene in human ovarian and colon tumors</article-title>
        <source>Cancer Res</source>
        <year>2001</year>
        <volume>61</volume>
        <issue>20</issue>
        <fpage>7426</fpage>
        <lpage>9</lpage>
        <?supplied-pmid 11606375?>
        <pub-id pub-id-type="pmid">11606375</pub-id>
      </element-citation>
    </ref>
    <ref id="CR66">
      <label>66</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Shalom</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Farago</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Pikarsky</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Katzav</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Vav1 mutations identified in human cancers give rise to different oncogenic phenotypes</article-title>
        <source>Oncogenesis</source>
        <year>2018</year>
        <volume>7</volume>
        <issue>10</issue>
        <fpage>80</fpage>
        <pub-id pub-id-type="doi">10.1038/s41389-018-0091-1</pub-id>
        <?supplied-pmid 30297765?>
        <pub-id pub-id-type="pmid">30297765</pub-id>
      </element-citation>
    </ref>
    <ref id="CR67">
      <label>67</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Coopman</surname>
            <given-names>PJ</given-names>
          </name>
          <name>
            <surname>Do</surname>
            <given-names>MT</given-names>
          </name>
          <name>
            <surname>Barth</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Bowden</surname>
            <given-names>ET</given-names>
          </name>
          <name>
            <surname>Hayes</surname>
            <given-names>AJ</given-names>
          </name>
          <name>
            <surname>Basyuk</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Blancato</surname>
            <given-names>JK</given-names>
          </name>
          <name>
            <surname>Vezza</surname>
            <given-names>PR</given-names>
          </name>
          <name>
            <surname>McLeskey</surname>
            <given-names>SW</given-names>
          </name>
          <name>
            <surname>Mangeat</surname>
            <given-names>PH</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells</article-title>
        <source>Nature</source>
        <year>2000</year>
        <volume>406</volume>
        <issue>6797</issue>
        <fpage>742</fpage>
        <pub-id pub-id-type="doi">10.1038/35021086</pub-id>
        <?supplied-pmid 10963601?>
        <pub-id pub-id-type="pmid">10963601</pub-id>
      </element-citation>
    </ref>
    <ref id="CR68">
      <label>68</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lazo</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>McQueeney</surname>
            <given-names>KE</given-names>
          </name>
          <name>
            <surname>Burnett</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Wipf</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Sharlow</surname>
            <given-names>ER</given-names>
          </name>
        </person-group>
        <article-title>Small molecule targeting of PTPs in cancer</article-title>
        <source>Int J Biochem Cell Biol</source>
        <year>2018</year>
        <volume>96</volume>
        <fpage>171</fpage>
        <lpage>81</lpage>
        <pub-id pub-id-type="doi">10.1016/j.biocel.2017.09.011</pub-id>
        <?supplied-pmid 28943273?>
        <pub-id pub-id-type="pmid">28943273</pub-id>
      </element-citation>
    </ref>
    <ref id="CR69">
      <label>69</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>van de Haar</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Canisius</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Michael</surname>
            <given-names>KY</given-names>
          </name>
          <name>
            <surname>Voest</surname>
            <given-names>EE</given-names>
          </name>
          <name>
            <surname>Wessels</surname>
            <given-names>LF</given-names>
          </name>
          <name>
            <surname>Ideker</surname>
            <given-names>T</given-names>
          </name>
        </person-group>
        <article-title>Identifying epistasis in cancer genomes: A delicate affair</article-title>
        <source>Cell</source>
        <year>2019</year>
        <volume>177</volume>
        <issue>6</issue>
        <fpage>1375</fpage>
        <lpage>83</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2019.05.005</pub-id>
        <?supplied-pmid 31150618?>
        <pub-id pub-id-type="pmid">31150618</pub-id>
      </element-citation>
    </ref>
    <ref id="CR70">
      <label>70</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <collab>Cancer Genome Atlas Research Network and others</collab>
          <etal/>
        </person-group>
        <article-title>Comprehensive genomic characterization defines human glioblastoma genes and core pathways</article-title>
        <source>Nature</source>
        <year>2008</year>
        <volume>455</volume>
        <issue>7216</issue>
        <fpage>1061</fpage>
        <pub-id pub-id-type="doi">10.1038/nature07385</pub-id>
        <pub-id pub-id-type="pmid">18772890</pub-id>
      </element-citation>
    </ref>
    <ref id="CR71">
      <label>71</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Brennan</surname>
            <given-names>CW</given-names>
          </name>
          <name>
            <surname>Verhaak</surname>
            <given-names>RG</given-names>
          </name>
          <name>
            <surname>McKenna</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Campos</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Noushmehr</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Salama</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Zheng</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Chakravarty</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Sanborn</surname>
            <given-names>JZ</given-names>
          </name>
          <name>
            <surname>Berman</surname>
            <given-names>SH</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The somatic genomic landscape of glioblastoma</article-title>
        <source>Cell</source>
        <year>2013</year>
        <volume>155</volume>
        <issue>2</issue>
        <fpage>462</fpage>
        <lpage>77</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2013.09.034</pub-id>
        <?supplied-pmid 24120142?>
        <pub-id pub-id-type="pmid">24120142</pub-id>
      </element-citation>
    </ref>
    <ref id="CR72">
      <label>72</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kochenberger</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Hao</surname>
            <given-names>J-K</given-names>
          </name>
          <name>
            <surname>Glover</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Lewis</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Lü</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <article-title>The unconstrained binary quadratic programming problem: a survey</article-title>
        <source>J Comb Optim</source>
        <year>2014</year>
        <volume>28</volume>
        <issue>1</issue>
        <fpage>58</fpage>
        <lpage>81</lpage>
        <pub-id pub-id-type="doi">10.1007/s10878-014-9734-0</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
